Log in to save to my catalogue

Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pa...

Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pa...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9160000

Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s

About this item

Full title

Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s

Publisher

Singapore: Springer Nature Singapore

Journal title

Acta pharmacologica Sinica, 2022-06, Vol.43 (6), p.1495-1507

Language

English

Formats

Publication information

Publisher

Singapore: Springer Nature Singapore

More information

Scope and Contents

Contents

Ulcerative colitis (UC) is a chronic inflammatory disease of the gastrointestinal tract, which is closely related to gut barrier dysfunction. Emerging evidence shows that interleukin-22 (IL-22) derived from group 3 innate lymphoid cells (ILC3s) confers benefits on intestinal barrier, and IL-22 expression is controlled by aryl hydrocarbon receptor (...

Alternative Titles

Full title

Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9160000

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9160000

Other Identifiers

ISSN

1671-4083

E-ISSN

1745-7254

DOI

10.1038/s41401-021-00781-7

How to access this item